• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489).

作者信息

Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A

机构信息

Center for Reproductive Medicine, Free University of Brussels, Belgium.

出版信息

Hum Reprod. 1993 Jun;8(6):863-5. doi: 10.1093/oxfordjournals.humrep.a138155.

DOI:10.1093/oxfordjournals.humrep.a138155
PMID:8345075
Abstract

This case report describes the first established pregnancy and birth after ovarian stimulation with Org 32489, pure recombinant human follicle stimulating hormone (recFSH, Organon International). A patient with tubal infertility participated in an open efficacy study of recFSH evaluating the efficacy of combined gonadotrophin-releasing hormone (GnRH)-agonist/recFSH treatment in women undergoing in-vitro fertilization (IVF) and embryo transfer. Ovarian stimulation was induced by recFSH in association with buserelin (Suprecur, 4 x 150 micrograms/day) using a short protocol. After 9 days of recFSH treatment (75 IU/day), six pre-ovulatory follicles (> or = 15 mm) were observed and 10,000 IU human chorionic gonadotrophin were administered. Nine mature oocytes were retrieved by oocyte puncture and after IVF, three embryos were replaced in the uterus. A viable singleton intra-uterine pregnancy was revealed at a gestational age of 7 weeks. The pregnancy progressed normally and ended with a vaginal delivery at a gestational age of 39.5 weeks. A healthy girl was born and paediatric examination did not demonstrate any abnormality.

摘要

相似文献

1
First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489).
Hum Reprod. 1993 Jun;8(6):863-5. doi: 10.1093/oxfordjournals.humrep.a138155.
2
First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization.使用嵌合长效人重组卵泡刺激素(FSH)激动剂(recFSH-CTP)进行体外受精后首次成功分娩。
Fertil Steril. 2003 Mar;79(3):621-3. doi: 10.1016/s0015-0282(02)04804-5.
3
Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens.重组人促卵泡生成素(Org 32489)联合不同促性腺激素释放激素激动剂方案的初步疗效研究的临床结果
Hum Reprod. 1994 Jun;9(6):1064-9. doi: 10.1093/oxfordjournals.humrep.a138634.
4
A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.两种卵巢刺激方案与促性腺激素释放激素(GnRH)拮抗剂联合治疗用于体外受精的随机比较,这两种方案分别是在周期第2天或第5天开始使用重组促卵泡激素并与标准长效GnRH激动剂方案进行对比。
J Clin Endocrinol Metab. 2003 Jan;88(1):166-73. doi: 10.1210/jc.2002-020788.
5
Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.重组卵泡刺激素和重组促黄体生成素联合 GnRH 拮抗剂方案与单独使用重组卵泡刺激素方案在年龄≥35 岁患者卵巢刺激中的随机对照研究。
Hum Reprod. 2015 May;30(5):1188-95. doi: 10.1093/humrep/dev038. Epub 2015 Mar 3.
6
[Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].国产高纯度尿促卵泡素对控制性卵巢刺激中体外受精-胚胎移植结局的影响
Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):838-42.
7
First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462).
Hum Reprod. 1998 Feb;13(2):294-5. doi: 10.1093/humrep/13.2.294.
8
Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.在促性腺激素释放激素拮抗剂多剂量方案中,重组促黄体生成素补充至重组促卵泡激素可诱导卵巢过度刺激。
Hum Reprod. 2005 May;20(5):1200-6. doi: 10.1093/humrep/deh741. Epub 2005 Jan 21.
9
A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.一项双盲、随机、剂量探索性研究,旨在评估促性腺激素释放激素拮抗剂加尼瑞克(Org 37462)预防接受重组促卵泡激素(果纳芬)进行卵巢刺激的女性过早出现促黄体生成素峰的疗效。加尼瑞克剂量探索性研究组。
Hum Reprod. 1998 Nov;13(11):3023-31.
10
A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
Hum Reprod. 1999 Oct;14(10):2442-7. doi: 10.1093/humrep/14.10.2442.

引用本文的文献

1
Assisted reproductive technology after the birth of louise brown.路易丝·布朗出生后的辅助生殖技术。
J Reprod Infertil. 2013 Jul;14(3):96-109.